Answers are grounded in this paper and cite their sources.
OBJECTIVES: Immunoassays are widely used for urine drug screening in hospital and emergency departments, but assay-dependent cross-reactivity may produce false-positive results. Labetalol and its metabolites have previously been associated with false-positive amphetamine immunoassay findings. We investigated an unexpected positive amphetamine screening result in a 45-year-old pregnant woman receiving labetalol. METHODS: The urine specimen was evaluated using two amphetamine immunoassay methods and subsequently investigated by ultrahigh-performance liquid chromatography-high-resolution tandem mass spectrometuy (UHPLC-HRMS/MS). Targeted HRMS was used to identify known compounds, whereas untargeted HRMS was applied to detect and prioritize unexpected features potentially relevant to the false-positive immunoassay result. Authentic reference standards, when available, were analyzed under identical LC-HRMS conditions to discriminate among relevant isobaric candidates. RESULTS: N feature for which 1-methyl-3-phenylpropylamine(3-amino-1-phenylbutane), a known minor labetalol metabolite, provided the highest spectral-library match. Phentermine and methamphetamine were among the isobaric candidates but were experimentally excluded by analysis of authentic standards. CONCLUSIONS: The contrasting immunoassay findings and HRMS results support an assay-dependent analytical interference and illustrate how targeted and untargeted HRMS can progressively refine the investigation of unexpected screening results. However, the tentatively identified labetalol metabolite candidate cannot be established as the cause of the nal von minden response without dedicated cross-reactivity experiments using a purified reference standard.
No takes yet. Share an insight, caveat, or question.
Karnani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: